Renal Disorders

Chronic kidney disease and end-stage renal failure strike one of every 10 Americans. The incidence is highest among people ages 65 and older, for whom the rate more than doubled between 2000 and 2008. As the population ages, this health care issue will become even more significant.

cellular structure attacking the kidney/renal system

Charles River has a long history of experience in the field of kidney disease research. Our expert scientists provide a wide range of capabilities to support your drug discovery programs.

There is a need to eliminate unpromising drug candidates as early as possible. In renal disorders, we offer a variety of models covering acute kidney injury to chronic kidney disease by leveraging expertise in procedures such as partial nephrectomies, renal ischemia-reperfusion injury, renovascular hypertension (Goldblatt 2-Kidney 1-Clip), and STZ-induced diabetes. The causes of kidney diseases are varied, but we can apply a variety of tools to assess potential new treatments.

Renal Disease Models

• Aminoglycoside nephrotoxicity
• Partial nephrectomies
• Age-induced renal disfunction
• Immunological methods of renal disfunction induction
• Renal ischemia-reperfusion injury
• Renovascular hypertension
• Renal transplantation
• Streptozotocin-induced diabetic nephropathy

Endpoint and Technical Capabilities

• Serum renal biomarkers
• Urine renal biomarkers
• Transdermal GFR assessment
• GFR assessment
• Effective renal plasma flow assessment
• Urine collection in metabolic cages
• Immunohistochemistry
• Microscopic examination of H & E stain, periodic acid-Schiff (PAS), and trichrome

Safety Assessment Services

We offer full-service support across the entire drug discovery and development continuum, including many products and services not specific to therapeutic area or indication.

Serving the needs of both small and large molecule developers, we offer a broad range of standard and specialized laboratory services to complement and enhance drug development programs, from discovery through safety and clinical trials. From complete IND-enabling programs to stand-alone assessments, our Safety Assessment team provides a full range of in vivo and in vitro testing services that comply with worldwide regulatory restrictions for the preclinical development of pharmaceuticals.

We provide a comprehensive range of testing programs and equipment to support pharmaceutical development. Our biologics testing solutions and portfolio of microbial quality control systems and services help clients ensure the safety, quality and compliance of their products. We support large molecule manufacturing from early preclinical formulation development through clinical and commercial manufacturing and release.

Exceptional support of the entire drug discovery and development process is a Charles River hallmark. As a customer-focused organization committed to advancing science and helping clients reach their goals, we continually strive to develop solutions that extend our support of their efforts. Because our industry-seasoned professionals have followed the same journey as our clients, we can provide insight into the bigger picture, advice on best practices, skilled staff to extend resources and targeted training to meet the unique challenges they face along the way.